Although the government announced measures to reinforce patient access to high-priced severe disease treatments on the 20th of last month, the pharmaceutical industry’s response to the new measures has been lukewarm at best. Moreover, the industry is ferociously criticizing how the government presented the measure without collecting industry opinion.

The main point of implementing the new measure was to reduce the reimbursement period while reinforcing post-marketing management, however, the industry is claiming that the measure will have little effect in reducing the reimbursement period while focusing too much on drug price reduction, ultimately further impeding patient access.

The